{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.3","upperLimit":"59.0","value":"33.3"},{"groupId":"OG001","lowerLimit":"33.5","upperLimit":"79.7","value":"57.9"},{"groupId":"OG002","lowerLimit":"39.9","upperLimit":"64.1","value":"52.1"},{"groupId":"OG003","lowerLimit":"37.2","upperLimit":"75.5","value":"57.1"},{"groupId":"OG004","lowerLimit":"19.7","upperLimit":"61.5","value":"39.1"},{"groupId":"OG005","lowerLimit":"5.0","upperLimit":"53.8","value":"23.1"},{"groupId":"OG006","lowerLimit":"52.8","upperLimit":"91.8","value":"76.2"},{"groupId":"OG007","lowerLimit":"19.2","upperLimit":"54.6","value":"35.5"},{"groupId":"OG008","lowerLimit":"58.8","upperLimit":"77.3","value":"68.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"105"}],"units":"Participants"}],"description":"Disease Control Rate was defined as Overall Response Rate or Stable Disease","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Pathologically proven diagnosis of biliary tract carcinoma","id":"OG000","title":"Biliary Tract Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of carcinoma of unknown primary site","id":"OG001","title":"Carcinoma of Unknown Primary Site Cohort"},{"description":"Patients with pathologically proven diagnosis of endometrial carcinoma","id":"OG002","title":"Endometrial Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of Ewing's Family of Tumors","id":"OG003","title":"Ewing's Family of Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of Germ Cell Tumors, excluding immature teratoma, or teratoma with malignant transformation.","id":"OG004","title":"Germ Cell Tumors Cohort"},{"description":"Patients with Pathologically proven diagnosis of Head and Neck Carcinoma. Salivary glands tumors were excluded.","id":"OG005","title":"Head and Neck Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of BRCA1/2-associated metastatic breast carcinoma","id":"OG006","title":"BRCA1/2-associated Metastatic Breast Carcinoma Cohort"},{"description":"Patients with Pathologically proven diagnosis of Neuroendocrine Tumors, grade 2 and 3 according to World Health Organization (WHO) classification.","id":"OG007","title":"Neuroendocrine Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of small cell lung cancer","id":"OG008","title":"Small Cell Lung Cancer Cohort"}],"paramType":"NUMBER","populationDescription":"Treated patients with disease measurement","reportingStatus":"POSTED","timeFrame":"From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6","title":"Disease Control Rate","type":"SECONDARY","unitOfMeasure":"percentage of paticipants"}